Pharmaceutical Executive Digest:
Having trouble viewing this e-mail? Click here.
Share with a colleague
Pharmaceutical Executive Europe  E-News
 
 
 
 
 

You can now follow us on Twitter at Twitter.com/pharmexecutive
 
Survey
We asked 60 pharma professionals, What is the greatest opportunity for the industry in the next 5 years?
Personalized medicine 52%
Renewed innovation 4%
Big data 12%
Emerging Markets 12%
Biosimilars 20%

Talk to us:
jupton@advanstar.com

Advertise with us:
wblow@advanstar.com

4 February, 2014
The EMA at 20: What Does It Want to Be?
The European Medicines Agency (EMA) is 20 years old this year — and it confronts many of the problems familiar to anyone at that age. After the vigorous growth and boundless optimism of its early adolescence, the agency now must make up its mind about what it wants to be, writes Reflector ...Read more
UK’s NICE in Funds Controversy: Who’s Watching the Drug Watchdogs?
It is nowadays fashionable to question everyone in authority; the drug industry and drug regulatory authorities have been among the most conspicuous targets of this intense monitoring. Now the UK’s National Institute for Health and Care Excellence has been accused by the British press of massive abuse of public funds ... Read more
On-Demand Marketing Re-Invents Customer Relationships
Staying on top of the marketing information stream can be difficult for your customers, but plans for a ‘holistic’ healthcare network could make relationships easier to manage, writes Peter Houston ... Read more
The Rise of Anna Protopapas, President, Millennium Takeda
William Looney speaks to Millennium Takeda’s new president, Anna Protopapas, who explains the life choices that brought her from Cyprus to Cambridge — and a lead position in the hotly contested search to make cancer a treatable disease ... Read more
Read the Pharm Exec Global Digest Regulatory Special
In this month’s Pharm Exec Global Digest — Regulating Cloud Computing; Regulators’ Three Goals for 2014; the European Regulatory Outlook; Obamacare and the US’s ‘New Medical Culture’’ and more ... Read more
Product Profile
Sciformix
Scignal Plus: Taking the Noise Out of Signal Detection
Scignal Plus provides superior, efficient signal detection by incorporating computational algorithms for a new method and previously known methods of signal detection. It has several distinct and important advantages over other products that are available in the market. Read More
Also in this issue
Global Biosimilars Market to Soar to $24 Billion by 2019
Innovation on the Rise in India
Senior Execs’ Anti-Social Social Media Behavior
Big Pharma’s Commercial Chiefs Head for Barcelona